Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.56B$4.56Bderived+22.5% vs Q4 2023 Net Income$563.00M$563.00Mderived+11.7% vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$3,095,000,000+20.0% Operating Incomederived$675,000,000+15.6% Operating Cash Flowderived$1,456,000,000+52.1% Free Cash Flowderived$1,179,000,000+70.9% Margins · derivedGross margin67.8%−1.4 pt vs Q4 2023
Operating margin14.8%−0.9 pt vs Q4 2023
Net margin12.3%−1.2 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 18, 2025 · 49 d after period end